| Quarterly Financials | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 399 | 426 | 425 | 437 | 484 | 555 | 441 | 557 | 539 | 628 | 437 | 533 | 602 | 712 | 607 | 623 | 654 | 773 | 660 | 784 | 803 | 1,017 | 832 | 932 | 883 | 933 | 840 | 908 | 962 | 1,037 |
| Expenses | 262 | 280 | 297 | 292 | 327 | 374 | 300 | 325 | 366 | 403 | 297 | 364 | 408 | 443 | 430 | 464 | 438 | 508 | 472 | 552 | 555 | 680 | 596 | 663 | 626 | 600 | 620 | 646 | 660 | 674 |
| EBITDA | 138 | 146 | 128 | 145 | 158 | 181 | 142 | 231 | 174 | 225 | 140 | 170 | 193 | 269 | 177 | 160 | 216 | 265 | 188 | 232 | 248 | 337 | 236 | 268 | 257 | 333 | 220 | 261 | 302 | 363 |
| Operating Profit % | 33 % | 32 % | 27 % | 30 % | 30 % | 30 % | 29 % | 30 % | 30 % | 34 % | 30 % | 30 % | 30 % | 33 % | 28 % | 24 % | 32 % | 33 % | 27 % | 28 % | 29 % | 32 % | 26 % | 27 % | 27 % | 35 % | 22 % | 27 % | 30 % | 34 % |
| Depreciation | 35 | 34 | 37 | 40 | 43 | 44 | 47 | 53 | 57 | 62 | 66 | 69 | 70 | 70 | 75 | 76 | 79 | 80 | 86 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 |
| Interest | 5 | 7 | 8 | 8 | 8 | 8 | 7 | 8 | 10 | 9 | 7 | 7 | 7 | 7 | 8 | 1 | 9 | 6 | 9 | 12 | 14 | 10 | 11 | 13 | 11 | 13 | 12 | 13 | 12 | 16 |
| Profit Before Tax | 98 | 104 | 83 | 97 | 107 | 129 | 87 | 170 | 107 | 153 | 66 | 94 | 117 | 192 | 95 | 82 | 128 | 179 | 93 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 241 |
| Tax | 16 | 20 | 17 | 19 | 20 | 29 | 15 | 42 | 15 | 33 | 8 | 10 | 14 | 32 | 17 | 16 | 24 | 31 | 19 | 28 | 30 | 52 | 30 | 34 | 27 | 20 | 26 | 31 | 50 | 57 |
| Net Profit | 82 | 85 | 66 | 78 | 87 | 100 | 72 | 128 | 92 | 120 | 58 | 84 | 102 | 161 | 77 | 67 | 104 | 148 | 74 | 102 | 110 | 179 | 93 | 117 | 112 | 189 | 76 | 106 | 131 | 183 |
| EPS in ₹ | 4.14 | 4.27 | 3.34 | 3.96 | 2.20 | 2.53 | 1.82 | 3.23 | 2.32 | 3.03 | 1.47 | 2.12 | 2.57 | 4.04 | 1.91 | 1.64 | 2.57 | 3.71 | 1.85 | 2.55 | 2.74 | 4.36 | 2.33 | 2.90 | 2.78 | 4.70 | 1.89 | 2.64 | 3.27 | 4.56 |
Syngene International
647.75
-2.50
(-0.38%)
There are new updates from the company1 day ago
View
Market Cap
26,074.30 Cr
EPS
12.71
PE Ratio
55.33
Dividend Yield
0.19 %
Industry
Healthcare52 Week High
960.60
52 Week Low
599.55
PB Ratio
5.53
Debt to Equity
0.17
Sector
Healthcare Technology
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
Company News
View All News
Syngene International Ltd. Block Trade on NSE2 days ago
A block trade of approximately 1,961,877 shares of Syngene International Ltd. occurred on the National Stock Exchange (NSE) for Rs. 128.42 crores. The trade was executed at a price of Rs. 654.60 per share.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
647.75 | #1 26,074.30 | #3 55.33 | #1 3,579.20 | #4 9.66 | #1 510 | #6 -2.81 | 48.83 | |
590.25 | 14,163.30 | 34.79 | 2,665.90 | 12.77 | 337 | 24.05 | 53.25 | |
231.40 | 5,046.20 | - | 32.80 | #1 49.09 | -105 | -65.66 | 74.43 | |
982.40 | 2,183.20 | 35.98 | 322.30 | 0.22 | 41 | 112.87 | 46.81 | |
78.36 | 184.54 | - | 769.70 | -22.39 | -59 | 133.33 | 54.39 | |
8.86 | 131.10 | - | 67.20 | -65.97 | -120 | #1 2,371.43 | 49.77 | |
40.32 | 63.88 | 91.64 | 40.30 | 8.04 | -1 | 120.00 | 45.13 | |
18.20 | 26.30 | #1 33.09 | 80.00 | -3.26 | 2 | -80.00 | 47.21 | |
24.80 | 15.60 | - | 9.80 | 40.00 | -9 | -450.00 | 56.42 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
9.66 %
Net Income Growth
9.82 %
Cash Flow Change
26.55 %
ROE
-6.70 %
ROCE
-3.05 %
EBITDA Margin (Avg.)
0.23 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 |
| Fixed Assets | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 |
| Current Assets | 1,720 | 1,764 | 1,613 | 1,807 | 2,206 | 2,425 | 1,959 |
| Capital Work in Progress | 155 | 274 | 234 | 237 | 346 | 177 | 838 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 919 | 548 |
| Other Assets | 1,846 | 1,337 | 1,133 | 1,743 | 1,791 | 2,069 | 1,916 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 |
| Current Liabilities | 784 | 1,129 | 1,539 | 1,133 | 1,229 | 1,188 | 1,144 |
| Non Current Liabilities | 685 | 607 | 448 | 929 | 1,037 | 1,025 | 750 |
| Total Equity | 1,720 | 1,968 | 2,176 | 2,821 | 3,298 | 3,618 | 4,258 |
| Reserve & Surplus | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 |
| Share Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 18 | -88 | 28 | 130 | -62 | -172 | -4 |
| Investing Activities | -349 | -646 | -424 | -629 | -611 | -653 | -494 |
| Operating Activities | 446 | 630 | 677 | 701 | 581 | 824 | 1,042 |
| Financing Activities | -79 | -72 | -226 | 58 | -31 | -343 | -552 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 70.58 % | 70.43 % | 70.42 % | 70.41 % | 70.41 % | 70.29 % | 64.86 % | 64.86 % | 54.88 % | 54.80 % | 54.79 % | 54.79 % | 54.79 % | 54.72 % | 54.72 % | 52.74 % | 52.74 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % | 0.02 % | 0.00 % | 0.00 % | 0.00 % | 20.92 % | 20.63 % | 20.72 % | 20.64 % | 19.47 % |
| DIIs | 4.02 % | 3.81 % | 4.03 % | 3.64 % | 3.26 % | 2.79 % | 4.96 % | 7.04 % | 10.73 % | 11.20 % | 9.94 % | 13.08 % | 15.80 % | 16.80 % | 17.48 % | 19.53 % | 21.50 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.05 % | 8.29 % | 8.46 % | 9.20 % | 9.22 % | 9.02 % | 8.81 % | 8.57 % | 8.39 % | 8.10 % | 7.53 % | 7.24 % | 6.45 % | 6.08 % | 5.45 % | 5.59 % | 5.08 % |
| Others | 17.35 % | 17.46 % | 17.09 % | 16.76 % | 17.11 % | 17.90 % | 21.36 % | 19.52 % | 25.98 % | 25.90 % | 27.73 % | 24.89 % | 2.03 % | 1.77 % | 1.62 % | 1.50 % | 1.21 % |
| No of Share Holders | 1,15,632 | 1,26,395 | 1,36,749 | 1,37,892 | 1,33,610 | 1,28,278 | 1,34,334 | 1,27,964 | 1,24,014 | 1,25,455 | 1,25,992 | 1,21,880 | 1,15,850 | 1,20,018 | 1,07,338 | 1,28,806 | 1,25,090 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 0.5 | 0.00 | 0.00 | 1 | 1.25 | 1.25 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.33 | 0.34 | 0.21 | 0.00 | 0.00 | 0.17 | 0.18 | 0.17 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Jul 2025 |  Annual General Meeting | NA | 23 Jul 2025 | 735.45 | 650.25 |
| 27 Jun 2025 |  Dividend | ₹ 1.25 /share | 27 Jun 2025 | 735.45 | 650.25 |
| 23 Apr 2025 |  Quarterly Result Announcement | NA | 23 Apr 2025 | 697.45 | 735.45 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 859.80 | 828.15 |
| 23 Oct 2024 | Quarterly Result Announcement | NA | 23 Oct 2024 | 884.35 | 838.90 |
| 24 Jul 2024 | Annual General Meeting | NA | 24 Jul 2024 | 701.05 | 757.75 |
| 28 Jun 2024 | Dividend | ₹ 1.25 /share | 28 Jun 2024 | 701.05 | 713.15 |
| 30 Jun 2023 | Dividend | ₹ 0.75 /share | 30 Jun 2023 | 625.90 | 759.60 |
| 30 Jun 2023 | Dividend | ₹ 0.50 /share | 30 Jun 2023 | 625.90 | 759.60 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 627.50 | 554.75 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 627.50 | 554.75 |
| 12 Jun 2019 |  Bonus | 1:1 | 11 Jun 2019 | 340.05 | 336.35 |
Announcements
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
9 hours ago
9 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation13 hours ago
13 hours agoCompliances-Reg.24(A)-Annual Secretarial Compliance1 day ago
1 day agoIntimation Of Cancellation Of Meeting With Analyst/Institutional Investor3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoIntimation Of Cancellation Of Meeting With Analyst/Institutional Investor6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2025
May 12, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011May 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 02, 2025
May 02, 2025Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)May 02, 2025
May 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 24, 2025
Apr 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 23, 2025
Apr 23, 2025Appointment Of Secretarial Auditors.Apr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-AllotmentApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Apr 23, 2025Audited Financial Results For Quarter & Year Ended March 31 2025.Apr 23, 2025
Apr 23, 2025Board Meeting Outcome for Outcome Of The Board Meeting - April 23 2025Apr 23, 2025
Apr 23, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 22, 2025
Apr 22, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 22, 2025
Apr 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 18, 2025
Apr 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 12, 2025
Apr 12, 2025Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results For The Quarter And Year Ending March 31 2025; And To Consider The Recommendation Of Final Dividend If Any.Apr 08, 2025
Apr 08, 2025Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Apr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Intimation Of An Update On The Tax Litigations.Mar 29, 2025
Mar 29, 2025Reminder - Communication To Shareholders For Claiming Unclaimed Dividends.Mar 28, 2025
Mar 28, 2025Intimation Of Disclosure On Receipt Of Order From The Income Tax Department.Mar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Intimation Of Additional Disclosure On Update On The Tax LitigationsMar 27, 2025
Mar 27, 2025Intimation Of Additional Disclosure On Receipt Of Orders From The Income Tax DepartmentMar 27, 2025
Mar 27, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Order From Income Tax DepartmentMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 24, 2025
Mar 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Order From Income Tax DepartmentMar 24, 2025
Mar 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 23, 2025
Mar 23, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 23, 2025
Mar 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Mar 10, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 07, 2025
Mar 07, 2025Technical Indicators
RSI(14)
Neutral 48.83
ATR(14)
Less Volatile 15.09
STOCH(9,6)
Neutral 72.52
STOCH RSI(14)
Overbought 90.29
MACD(12,26)
Bullish 4.89
ADX(14)
Weak Trend 19.86
UO(9)
Bearish 59.04
ROC(12)
Uptrend But Slowing Down 2.91
WillR(14)
Neutral -21.27
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 UTI Innovation Fund Direct - Growth | 267976 | 2.24% | -1.73% | -1.46% | Apr 2025 | |
 Mirae Asset Healthcare Fund Direct - Growth | 727181 | 1.72% | -1.29% | -1.23% | Apr 2025 | |
 DSP Focus Direct Plan-Growth | 375562 | 0.96% | 0.93% | 0.96% | Apr 2025 | |
 Bandhan Aggressive Hybrid Fund Direct-Growth | 92927 | 0.70% | -0.68% | -0.69% | Apr 2025 | |
| Mirae Asset Multicap Fund Direct - Growth | 0 | 0.00% | -0.64% | -0.62% | Apr 2025 | |
 LIC MF Healthcare Fund Direct - Growth | 39372 | 2.97% | -0.60% | -0.49% | Apr 2025 | |
| DSP Multicap Fund Direct - Growth | 891518 | 2.73% | -0.58% | -0.52% | Apr 2025 | |
| DSP ELSS Tax Saver Fund Direct Plan-Growth | 3556911 | 1.36% | 0.58% | 0.88% | Apr 2025 | |
 Samco Multi Asset Allocation Fund Direct-Growth | 0 | 0.00% | -0.57% | -0.56% | Apr 2025 | |
| UTI Mid Cap Fund Direct-Growth | 1209192 | 0.70% | -0.56% | -0.52% | Apr 2025 | |
| Mirae Asset Arbitrage Fund Direct - Growth | 339000 | 0.70% | 0.55% | 0.56% | Apr 2025 | |
| DSP Equity Opportunities Fund Direct Plan-Growth | 3212765 | 1.42% | 0.55% | 0.94% | Apr 2025 | |
 HSBC India Export Opportunities Fund Direct-Growth | 242000 | 0.94% | -0.54% | -0.45% | Apr 2025 | |
| DSP Midcap Direct Plan-Growth | 1586541 | 0.57% | 0.53% | 0.57% | Apr 2025 | |
 ICICI Prudential Long Term Wealth Enhancement Fund Direct - Growth | 14424 | 2.33% | -0.44% | -0.29% | Apr 2025 | |
 Navi Nifty Midcap 150 Index Fund Direct - Growth | 0 | 0.00% | -0.44% | -0.41% | Apr 2025 | |
 Bajaj Finserv Healthcare Fund Direct-Growth | 131483 | 2.69% | -0.42% | -0.34% | Apr 2025 | |
| UTI Focused Fund Direct - Growth | 607899 | 1.50% | -0.41% | -0.32% | Apr 2025 | |
 PGIM India Healthcare Fund Direct-Growth | 35005 | 2.06% | -0.38% | -0.31% | Apr 2025 | |
| UTI ELSS Tax Saver Fund Direct-Growth | 571367 | 0.98% | -0.38% | -0.31% | Apr 2025 | |
| ICICI Prudential MNC Fund Direct - Growth | 616316 | 2.43% | -0.37% | -0.18% | Apr 2025 | |
 Tata Nifty MidSmall Healthcare Index Fund Direct - Growth | 46357 | 2.18% | -0.32% | -0.23% | Apr 2025 | |
| Mirae Asset Aggressive Hybrid Fund Direct-Growth | 471560 | 0.34% | -0.31% | -0.28% | Apr 2025 | |
| HSBC Flexi Cap Fund Direct-Growth | 221000 | 0.30% | -0.30% | -0.29% | Apr 2025 | |
| Bandhan Innovation Fund Direct-Growth | 417986 | 1.85% | -0.30% | -0.29% | Apr 2025 |
About Syngene International
Syngene International Limited is an integrated research, development, and manufacturing services company headquartered in India. It serves global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company operates across four business divisions: Discovery Services, Development Services, Manufacturing Services, and Dedicated Centers. With approximately 6000 scientists, Syngene has facilities spanning 2.2 million sq. ft. in Bangalore, Hyderabad, and Mangalore. It provides end-to-end services within Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Syngene offers various platforms and services including drug discovery, development capabilities, custom synthesis, process R&D, cGMP manufacturing, and clinical development services. The company has partnerships and collaborations with multiple global pharmaceutical and healthcare companies, expanding its research and manufacturing capabilities over the years.
Listing Date
11 Aug, 2015(9 Years,
49 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
